Valneva Se · EURONEXT:VLA
Valneva — H1 2026 Earnings Presentation
21 slides from Valneva's earnings presentation, Aug 13, 2026
Slide 1: A Leading Specialty Vaccine Company
A Leading Specialty Vaccine Company First Half 2026 Financial Results and Business Update
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer Certain information and statements included in this presentation are not historical facts to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to but are for
Slide 3: Agenda
Agenda Introduction Business Update Financial Report H1 2026 Business and Financial Outlook Q&A 3
Slide 4: H1 2026 Financial and Business Highlights
H1 2026 Financial and Business Highlights Lyme Disease Vaccine Enhanced Financial Position Candidate Advancing €121.5m in Cash Pfizer expects regulatory decisions Reflects disciplined cash management in next 12 month1 and proceeds from recent offering2 H1 2026 €64.0m Total Product Sales Restructurin
Slide 5: Agenda
Agenda Introduction Business Update Financial Report H1 2026 Business and Financial Outlook Q&A 5
Slide 6: LB6V / VLA15 World's leading Lyme Disease Vaccine Candidate
LB6V / VLA15 World’s leading Lyme Disease Vaccine Candidate
Slide 7: LB6V (formerly VLA15) Demonstrates Strong Efficacy in Phase 3
LB6V (formerly VLA15) Demonstrates Strong Efficacy in Phase 31 Results strengthen confidence - Pfizer expects regulatory decisions in the next 12 months2 Vaccine Efficacy Safety Pre-specified Analysis Vaccine candidate was well tolerated Efficacy (95% CI) (Season 2) From Day 28 post-dose 4 73% (16,
Slide 8: Lyme Disease Represents A Major Medical Need And Market Opportunity
Lyme Disease Represents A Major Medical Need And Market Opportunity No vaccine is currently available to prevent Lyme disease in humans Commercial opportunity for Valneva Annual Burden of Disease U.S. : ~476K cases Europe : >132K cases Severe Manifestations3 10-30% cases develop • Lyme carditis • Ly
Slide 9: LB6V is a Compelling Opportunity in an Underserved Market
LB6V is a Compelling Opportunity in an Underserved Market First-Mover Differentiated Compelling Strategic Fit Attractive Advantage in Highly Product Profile Target Population with Pfizer’s Vaccine Commercial Receptive Market and Use Case Franchise Dynamics Only Lyme disease Proven MoA with Broad add
Slide 10: IXCHIQ / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
IXCHIQ® / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
Slide 11: IXCHIQ: Focused on Confirming Efficacy/Safety and Expanding Access
IXCHIQ®: Focused on Confirming Efficacy/Safety and Expanding Access Robust clinical program supported by CEPI grant Pilot Vaccination Campaign Ongoing (Brazil) To serve as the basis for post-marketing commitment studies • Launched in February 2026 with partner Instituto Butantan in select municipali
Slide 12: S4V2 World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
S4V2 World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
Slide 13: S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease
S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease Tetravalent bioconjugate vaccine with potential to cover up to ~85% of shigellosis infections1 Vaccine Market Key Highlights Opportunity Milestones World’s most clinically advanced Global market expected to exceed Pha
Slide 14: Agenda
Agenda Introduction Business Update Financial Report H1 2026 Business and Financial Outlook Q&A 14
Slide 15: First Half 2026 Financials: Product Sales
First Half 2026 Financials: Product Sales Primarily reflects discontinuation of third-party sales, 2025 outbreak events, and distributor transition €m (audited) H1 2026 H1 2025 IXIARO®/JESPECT® 44.0 54.7 DUKORAL® 14.7 17.4 IXCHIQ® 4.4 7.5 Third-party products 1.0 11.4 Total product sales 64.0 91.0 P
Slide 16: First Half 2026 Financials: Income Statement
First Half 2026 Financials: Income Statement €m (audited) H1 2026 H1 2025 Product sales 64.0 91.0 Other Revenues 1.8 6.5 Revenues 65.8 97.6 Cost of goods and services (59.5) (47.2) Research and development expenses (30.2) (32.4) Marketing and distribution expenses (13.5) (20.3) General and administr
Slide 17: Agenda
Agenda Introduction Business Update Financial Report H1 2026 Business and Financial Outlook Q&A 17
Slide 18: Financial Outlook
Financial Outlook 2026 Sales Guidance Financial Outlook Product Sales: €135 - €150 million (reiterated); Continued cash flows from proprietary Commercial business expected to remain cash- commercialized vaccines flow positive Restructuring program implemented with positive P&L and cash flow impacts
Slide 19: Our Next Phase as a Leading Vaccine Biotech Company
Our Next Phase as a Leading Vaccine Biotech Company Potential LB6V Success Would Offer Strategic Growth Opportunities Leverage core strengths in vaccine development to deliver greater long-term value Key initiatives: Build scale in R&D pipeline post-LB6V exit • Strategic in-licensing/M&A to augment
Slide 20: Agenda
Agenda Introduction Business Update Financial Report H1 2026 Business and Financial Outlook Q&A 20
Slide 21: Thank you
Thank you Merci Danke Tack valneva